Dr. J David Warren

PhD

J David Warren, PhD, is a dedicated scientist, drug hunter, and entrepreneur with over 20 years of experience as a biomedical researcher. He was born and raised in Colorado, where he lived through his college and graduate school years. Dr. Warren earned his PhD from Colorado State University, where he received a graduate fellowship from Boehringer Ingelheim. He then moved to New York City to complete postdoctoral studies at the Memorial Sloan Kettering Cancer Center under the mentorship of Samuel J. Danishefsky as an NIH-supported fellow. Afterwards, he began his independent career at Weill Cornell Medicine, where he led a laboratory focused on bioorganic and medicinal chemistry, placing several compounds into preclinical development.

Dr. Warren’s accomplishments include developing novel methodology for the total chemical synthesis of fully glycosylated proteins, synthesizing new photostable fluorophores for single-molecule imaging, creating novel therapeutics for treating Niemann-Pick type C (NPC) disease, discovering nucleoside analogs active against adenosine kinase, finding selective inhibitors of HCN1 for neuropathic pain treatment, identifying novel PET tracers for imaging the chemokine receptor CXCR4, pinpointing a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancer, and discovering and developing inhibitors that are selective for mycobacterial versus human proteasomes. Additionally, he contributed to the CURE-PRO platform, an innovative approach to targeted protein degradation.

Dr. Warren currently serves on the Scientific Advisory Board of Akelos, Inc., is a Senior Principal Scientist at Canary Oncoceutics, and is a Senior Advisor to Dyo Biotechnologies and Eresina Labs. He holds 16 issued US and international patents and has published over 50 peer-reviewed publications and book chapters.